The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats

Pharmacology and Toxicology

Volumn 93, Issue 2, 2003, Pages 66-70

  Gilgun Sherki, Yossi ^a   Melamed, Eldad ^a   Mechoulam, Raphael ^b   Offen, Daniel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CARBIDOPA; DEXANABINOL; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; OXIDOPAMINE; TETRAHYDROCANNABINOL; CANNABINOID; DRUG DERIVATIVE; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; CELL MEMBRANE FLUIDITY; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG INDUCED DISEASE; ENANTIOMER; EXTRAPYRAMIDAL SYMPTOM; GLOBUS PALLIDUS; MALE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; VOLUNTARY MOVEMENT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; INJURY; MOTOR ACTIVITY; ROTATION; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA; TUMOR CELL LINE;

ANIMALIA; CANNABIS;

ANIMALS; APOMORPHINE; CANNABINOIDS; CARBIDOPA; CELL LINE, TUMOR; LEVODOPA; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; ROTATION; SUBSTANTIA NIGRA; TETRAHYDROCANNABINOL;

EID: 0042530283     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2003.930202.x     Document Type: Article

References (33)

1. 2 agonist in rats with unilateral lesions of the nigrostriatal pathway. Brain Res. 1995, 691, 106-114.
2. Consroe, P.: Brain cannabinoid system as target for the therapy of neurological disorders. Neurobiol Dis. 1998, 5, 534-551.
3. Crossman, A. R.: A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov. Disord. 1990, 5, 100-108.
4. Davis, T. L., G. Brughitta, F. Baronti & M. M. Mouradian: Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics. Neurology 1991, 41, 630-633.
5. Di Marzo, V., D. Meleck, T. Bisogno & L. De petrocellis: Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends in Neuroscience 1998, 21, 521-528.
6. Eshhar, N., S. Striem, R. Kohen, O. Tirosh & A. Biegon: Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur. J. Pharmacol. 1995, 283, 19-29.
7. Feigenbaum, J. J., F. Bergman, S. A. Richmond, R. Mechoullam, V. Nadler, Y. Kloog & M. Sokolovsky: Nonpsychotrophic cannabinoid acts as a functional N-methl-D-aspartate receptor blocker. Proc. Natl. Acad. Sci. USA 1989, 86, 9584-9587.
8. 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA 1998, 95, 8268-8273.
9. Hefti, F., E. Melamed & R. J. Wurtman: The decarboxylation of DOPA in the parkinsonian brain: in vivo studies in animal models. J. Neural Transm. 1980, Suppl 16, 95-101.
10. Henry, B., A. R. Crossman & J. M. Brotchie: Characterization of enhanced behavioral response to levodopa following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 1998, 151, 334-342.
11. Herkenham, M., A. B. Lynn, B. R. Costa & E. K. Richfield: Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 1991, 547, 267-274.
12. Hiltunen, A. G., T. U. Jarbe & K. Wangdahl: Cannabinol and cannabidiol in combination: temperature, open-field activity, and vocalization. Pharmacol. Biochem. Behav. 1988, 30, 675-678.
13. Hochman, A., H. Sternin, S. Gorodin, S. Korsmeyer, I. Ziv, E. Melamed & D. Offen: Enhanced oxidative stress and altered antioxidants in brains of bcl-2 deficient mice. J. Neurochem. 1998, 71, 741-748.
14. Hudson, J. L., V. H. G. Craig, I. Stromberg, S. Brock, J. Clayton, J. Masserano, B. J. Hoffer & G. A. Gerhardt: Correlation of apomorphine and amphetamine-induced turning with nigrostriatal dopamine content in inilateral 6-hydroxydopamine lesioned rats. Brain Res. 1993, 626, 167-174.
15. Mailleux, P. & J. J. Vanderhaeghen: Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J. Neurochem. 1993, 61, 1705-1712.
16. Mechoulam, R., J. J. Feigenbaum, M. Lander, M. Segal, T. U. Jarbe, A. J. Hiltunen & P. Consroe: Enantiomeric cannabinoids: stereospecificity of psychotrophic activity. Experientia 1988, 44, 762-764.
17. Mechoulam, R., N. Lauder, A. Breuer & J. Zahalaka: Synthesis of the individual pharmacologically distinct enantiomers of tetrahydrocannabinol derivatives. Tetrahedron: Assymetry 1990, 1, 315-319.
18. Mechoulam, R. & S. Ben-Shabat: From Gan-Zi-Gun-Nu to anandamide and 2-arachidonoyl-glycerol, the ongoing story of cannabis. Nat. Prod. Rep. 1999, 16, 131-143.
19. Melamed, E., D. Offen, A. Shirvan & I. Ziv: Levodopa- an exotoxin or a therapeutic drug. J. Neurol. 2000, 247 Suppl 2, II135-139.
20. Melamed, E., F. Hefti & R. J. Wurtman: Nonaminergic striatal neurons convert exogenous L-DOPA to dopamine in Parkinsonism. Ann. Neurol. 1980, 8, 558-563.
21. Muller-Vahl, K. R., H. Kolbe, U. Schneider & H. M. Emrich: Cannabis in movement disorders. Res. in Complement Med. 1996, 6, 23-27.
22. Ovadia, H., A. Wohlman, R. Mechoulam & R. Weidenfeld: Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology 1995, 34, 175-180.
23. Paxinos, G. & C. Watson: The rat brain in stereotaxic coordinate. New York, Academic Press, 1986.
24. Perese, D. A., J. Ulman, J. Viola, S. E. Ewing & K. S. Bankiewicz: A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res. 1989, 494, 285-293.
25. Piomelli, D., A. Giuffrida, A. Calignano & F. Rodriguez de Fonseca: The endocannabinoids system as a target for therapeutic drugs. TIPS 2000, 21, 482-486.
26. Sanudo-pena, M. C., S. L. Patrick, R. L. Patrick & J. M. Walker: Effects of intranigral cannabinoids on rotational behavior in rats: interactions with the dopaminergic system. Neurosci. Letters 1996, 206, 21-24.
27. Sanudo-pena, M. C. & J. M. Walker: Role of the subthalamic nucleus on cannabinoid actions in the substantia nigra of the rat. J. Neurophysiol. 1997, 77, 1635-1638.
28. Sanudo-pena, M. C., S. L. Patrick, S. Khen, R. L. Patrick, K. Tsou & J. M. Walker: Cannabinoid effects in basal ganglia in rat model of Parkinson's disease. Neurosci. Letters 1998, 248, 171-174.
29. Self, D. W.: Anandamide: a candidate neurotransmitter heads for the big leagues. Nature Neuroscience 1999, 2, 303-304.
30. Shohami, E., J. Weidenfeld, H. Ovadia, Z. Vogel, L. Hanus, E. Fride, A. Breuer, S. Ben-shabat, T. Sheskin & R. Mechoulam: Endogenous and synthetic cannabinoids: recent advances. CNS Drug Reviews 1996, 2, 429-451.
31. Sieradzan, K. A., S. H. Fox, M. Hill, J. Dick, A. R. Crossman & J. M. Brotzhie: Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: A pilot study. Neurology 2001, 57, 2108-2111.
32. Tchilibon, S. & R. Mechoulam: Synthesis of a primary metabolite of cannabidiol. Org Letters 2000, 2, 3301-3303.
33. Verhagen, M. L., P. Del dotto, P. Van den Munckhof, J. Fang, M. M. Mouradian & T. N. Chase: Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson disease. Neurology 1998, 50, 1323-1326.